Stealth BioTherapeutics Corp. (MITO)

NASDAQ: MITO · Delayed Price · USD
0.234
-0.011 (-4.45%)
At close: May 18, 2022 4:00 PM
0.230
-0.005 (-1.964%)
Pre-market:May 19, 2022 7:02 AM EDT
Market Cap14.05M
Revenue (ttm)n/a
Net Income (ttm)-52.53M
Shares Out59.97M
EPS (ttm)-0.92
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume686,169
Open0.248
Previous Close0.245
Day's Range0.227 - 0.265
52-Week Range0.175 - 2.100
Beta1.88
AnalystsBuy
Price Target2.41 (+929.0%)
Earnings DateMay 17, 2022

About MITO

Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate is Elamipretide that is in phase 3 clinical trial to treat barth syndrome, phase 2/3 clinical trial for the treatment of duchenne cardiomyopathy, phase 2a clinical trial to treat friedreich's ataxia, phase 2 clinical trial for the treatment of dry age-related macular degeneration, phase 2 clinical trial to treat leber's heredit...

IndustryBiotechnology
IPO DateFeb 15, 2019
Employees38
Stock ExchangeNASDAQ
Ticker SymbolMITO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for MITO stock is "Buy." The 12-month stock price forecast is 2.41, which is an increase of 929.04% from the latest price.

Price Target
$2.41
(929.04% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Stealth BioTherapeutics Receives Orphan Drug Designation from FDA for Elamipretide for Treatment of Duchenne Muscular...

Pre-IND meeting request granted by FDA's Division of Neurology I BOSTON , May 12, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the ...

1 week ago - PRNewsWire

What to Know About Buying Penny Stocks on May 10th

Here's what you need to know about trading penny stocks today The post What to Know About Buying Penny Stocks on May 10th appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks...

Other symbols:FREQIMTE
1 week ago - PennyStocks

Stealth Bio Posts Disappointing Elamipretide Data From Mid-Stage Geographic Atrophy Study

Stealth BioTherapeutics Corp (NASDAQ: MITO) has announced topline data from its Phase 2 ReCLAIM-2 trial evaluating elamipretide in geographic atrophy (GA) secondary to dry age-related macular degenerati...

2 weeks ago - Benzinga

STEALTH BIOTHERAPEUTICS ANNOUNCES DATA FROM RECLAIM-2 PHASE 2 TRIAL OF ELAMIPRETIDE IN GEOGRAPHIC ATROPHY

Study did not meet primary endpoints of mean change in low luminance visual acuity (LLVA) and geographic atrophy (GA) progression Categorical improvement in LLVA, with >15% of elamipretide-treated patie...

2 weeks ago - PRNewsWire

Stealth BioTherapeutics Announces $8.5 Million in Equity Financings

BOSTON , April 11, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO) (the "Company"), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...

1 month ago - PRNewsWire

Stealth BioTherapeutics Announces New SBT-272 Data and Trial Initiation

BOSTON , March 30, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapie...

1 month ago - PRNewsWire

Stealth BioTherapeutics Receives Orphan Drug Designation from FDA for Elamipretide for the Treatment of Friedreich's ...

Phase 2a clinical trial in Friedreich's ataxia has been initiated and is currently recruiting patients BOSTON , March 28, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq:MITO), a clinical-stag...

1 month ago - PRNewsWire

Stealth BioTherapeutics Announces New Data on Complement Gene Expression and Cell Survival in Dry AMD to be Presented...

BOSTON , March 24, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapie...

1 month ago - PRNewsWire

Stealth BioTherapeutics to Host Virtual Event on the Potential of Elamipretide in Treatment of Geographic Atrophy in ...

BOSTON , March 17, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies...

2 months ago - PRNewsWire

Stealth BioTherapeutics Showcases New Duchenne Muscular Dystrophy Nonclinical Data at the 2022 Muscular Dystrophy Ass...

BOSTON, March 16, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies ...

2 months ago - PRNewsWire

Stealth BioTherapeutics to Present at Upcoming March Investor Conferences

BOSTON , March 9, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies ...

2 months ago - PRNewsWire

Stealth BioTherapeutics to Present at Mitochondria-Targeted Drug Development Summit

BOSTON, Feb. 22, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies f...

2 months ago - PRNewsWire

Last Patient Completes Treatment in Stealth BioTherapeutics' Phase 2 Geographic Atrophy Clinical Trial

BOSTON, Feb. 15, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies f...

3 months ago - PRNewsWire

Stealth BioTherapeutics Receives Nasdaq Notification Regarding Minimum Market Value Of Publicly Held Shares Requirement

BOSTON , Feb. 11, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies ...

3 months ago - PRNewsWire

Stealth BioTherapeutics Announces Oral Presentation of New Duchenne Muscular Dystrophy Data at the 2022 Muscular Dyst...

BOSTON, Feb. 8, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies f...

3 months ago - PRNewsWire

Stealth BioTherapetuics Receives Nasdaq Notifications Regarding Minimum Bid And Market Value Requirements

BOSTON, Jan. 7, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies fo...

4 months ago - PRNewsWire

Stealth BioTherapeutics to Present at 2022 H.C. Wainwright BioConnect Virtual Conference

BOSTON, Jan. 4, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies f...

4 months ago - PRNewsWire

Stealth BioTherapeutics Reports Positive Pre-IND Meeting for Duchenne Muscular Dystrophy

BOSTON, Dec. 20, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies f...

4 months ago - PRNewsWire

Stealth BioTherapeutics Provides Update On Clinical Stage Rare Disease Programs

BOSTON, Dec. 13, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies f...

5 months ago - PRNewsWire

Stealth BioTherapeutics Reports Third Quarter 2021 Financial Results and Recent Business Highlights

BOSTON, Nov. 11, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies f...

6 months ago - PRNewsWire

Stealth BioTherapeutics to Report Third Quarter Financial Results on Thursday, November 11

BOSTON, Nov. 4, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies fo...

6 months ago - PRNewsWire

Stealth Bio Stock Falls On FDA Refusal to File Letter For Barth Syndrome Candidate

Stealth BioTherapeutics Corp (NASDAQ: MITO) has received a Refusal to File letter from the FDA regarding its marketing application for elamipretide, a mitochondria-targeted therapy for Barth syndrome. B...

6 months ago - Benzinga

Stealth BioTherapeutics Receives Refusal to File Letter from the FDA

BOSTON, Oct. 20, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies ...

6 months ago - PRNewsWire

Stealth BioTherapeutics Presents Positive SBT-272 Preclinical Data at 2021 Annual Northeast Amyotrophic Lateral Scler...

BOSTON, Oct. 7, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies fo...

7 months ago - PRNewsWire

Stealth BioTherapeutics Completes a $25 Million Debt Financing with Horizon Technology Finance

BOSTON, Oct. 4, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies f...

Other symbols:HRZN
7 months ago - PRNewsWire